Hims(US:HIMS) Prnewswire·2025-06-25 18:08Core Viewpoint - Hims & Hers Health, Inc. experienced a significant share price drop of over 30% following the termination of its collaboration with Novo Nordisk due to concerns regarding sales practices and marketing of the weight loss drug Wegovy® [1][4]. Company Summary - Hims & Hers Health, Inc. had previously partnered with Novo Nordisk to provide access to Wegovy®, which is FDA-approved for obesity treatment, through its platform [3]. - The partnership was short-lived, as Novo Nordisk cited "illegal mass compounding and deceptive marketing" as reasons for the termination [4]. - Hims & Hers had previously assured investors of its regulatory compliance, claiming it was not bypassing the regulatory process [2]. Investigation Summary - Hagens Berman, a national shareholders rights firm, has initiated an investigation into potential violations of securities laws by Hims & Hers, urging affected investors to report their losses [2]. - The investigation will focus on whether Hims & Hers misled investors regarding the marketing of potentially unsafe versions of Wegovy® [4].